PAVmed and Lucid Diagnostics to Provide Strategic Business Update
11 1월 2023 - 10:00PM
Business Wire
Companies to host Conference Call at 4:30 PM
EDT on Tuesday, January 17, 2023
PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified
commercial-stage medical technology company operating in the
medical device, diagnostics, and digital health sectors, and its
majority-owned subsidiaries Lucid Diagnostics Inc. (Nasdaq: LUCD),
a commercial-stage cancer prevention diagnostics company, and Veris
Health Inc., a digital health company focused on enhanced
personalized cancer care, today announced they will hold a joint
conference call to provide a strategic business update on Tuesday,
January 17, 2023 at 4:30PM EDT.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230111005361/en/
On the call, management will present planned refinements to each
company’s business strategy as each continues to drive
commercialization of its leading products to benefit patients in
need and create value for shareholders.
To access the conference call, listeners should dial
877-407-3982 toll-free in the U.S. or 201-493-6780 and ask to join
the “PAVmed and Lucid Diagnostics Strategic Business Update
Conference Call”. The conference call will be available live at the
investor relations section of PAVmed’s website at ir.pavmed.com and
the investor relations section of Lucid Diagnostics’ website at
ir.luciddx.com. Following the conclusion of the conference call, a
replay will also be available for one week and can be accessed by
dialing 844-512-2921 toll-free in the U.S. or 412-317-6671,
followed by the PIN number 13735527.
About PAVmed and Lucid Diagnostics
PAVmed Inc. is a diversified commercial-stage medical technology
company operating in the medical device, diagnostics, and digital
health sectors. Its majority-owned subsidiary, Lucid Diagnostics
Inc. (Nasdaq: LUCD), is a commercial-stage cancer prevention
medical diagnostics company that markets the EsoGuard® Esophageal
DNA Test and EsoCheck® Esophageal Cell Collection Device—the first
and only commercial tools for widespread early detection of
esophageal precancer to prevent esophageal cancer deaths. PAVmed’s
other majority-owned subsidiary, Veris Health Inc., is a digital
health company focused on enhanced personalized cancer care through
remote patient monitoring using implantable biologic sensors with
wireless communication along with a custom suite of connected
external devices.
For more information, please visit www.pavmed.com and
www.luciddx.com .
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of PAVmed’s and Lucid Diagnostics’ management, are
subject to risks and uncertainties, which could cause actual
results to differ from the forward-looking statements. Risks and
uncertainties that may cause such differences include, among other
things, volatility in the price of PAVmed’s and Lucid Diagnostics’
common stock; general economic and market conditions; the
uncertainties inherent in research and development, including the
cost and time required to advance PAVmed’s and Lucid Diagnostics’
products to regulatory submission; whether regulatory authorities
will be satisfied with the design of and results from PAVmed’s and
Lucid Diagnostics’ clinical and preclinical studies; whether and
when PAVmed’s and Lucid Diagnostics’ products are cleared by
regulatory authorities; market acceptance of PAVmed’s and Lucid
Diagnostics’ products once cleared and commercialized; PAVmed’s and
Lucid Diagnostics’ ability to raise additional funding as needed;
and other competitive developments. In addition, PAVmed and Lucid
Diagnostics continue to monitor the COVID-19 pandemic and the
pandemic’s impact on PAVmed’s and Lucid Diagnostics’ businesses.
These factors are difficult or impossible to predict accurately and
many of them are beyond PAVmed’s and Lucid Diagnostics’ control. In
addition, new risks and uncertainties may arise from time to time
and are difficult to predict. For a further list and description of
these and other important risks and uncertainties that may affect
PAVmed’s future operations, see Part I, Item 1A, “Risk Factors,” in
PAVmed’s most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, as the same may be updated in
Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form
10-Q filed by PAVmed after its most recent Annual Report. For a
further list and description of these and other important risks and
uncertainties that may affect Lucid Diagnostics’ future operations,
see Part I, Item 1A, “Risk Factors,” in Lucid Diagnostics’ most
recent Annual Report on Form 10-K filed with the Securities and
Exchange Commission, as the same may be updated in Part II, Item
1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by
Lucid Diagnostics after its most recent Annual Report. Each of
PAVmed and Lucid Diagnostics disclaims any intention or obligation
to publicly update or revise any forward-looking statement to
reflect any change in its expectations or in events, conditions, or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230111005361/en/
Investor and Media:
Michael Parks PAVmed and Lucid Diagnostics 484.356.7105
mep@pavmed.com
PAVmed (NASDAQ:PAVMZ)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
PAVmed (NASDAQ:PAVMZ)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024